" Allergan ' s businesses align with and enhance Pfizer ' s businesses , creating best in class , sustainable , innovative and established businesses that are poised for growth . Through this combination , Pfizer will have greater financial flexibility that will facilitate our continued discovery and development of new innovative medicines for patients , direct return of capital to shareholders , and continued investment in the United States , while also enabling our pursuit of business development opportunities on a more competitive footing within our industry , " said Ian Read Chief Executive Officer , Pfizer .
